Bet on 5 Top-Ranked Stocks With Rising P/E

The article promotes a “rising P/E” stock-picking screen, arguing that steady P/E increases can signal improving earnings expectations and potential upside. It narrows 7,700+ stocks to 45 using EPS-growth and multi-horizon price-strength filters versus the S&P 500, then highlights five names: ADVM (avg four-quarter earnings surprise +5.15%), ICCM (+4.76%), DRIO (+53.22%), WATT (+10.30%), and SPCE (+18.28%). Overall, it frames these setups as likely catalysts for near-term “price pops,” but provides no new macro or company-specific news outside the screen metrics.

Analysis

This screen is less about valuation and more about reflexive flows: rising P/E in microcaps usually means price is outrunning a denominator that is either still immature or about to be revised, which is a momentum signal, not a quality signal. That works best over days to a few weeks when liquidity is improving and positioning is crowded to the short side; it works much worse over 1-3 months if there is no hard catalyst to force estimate revisions.

The key second-order effect is financing. In the pre-profit names, any share-price strength can lower near-term dilution pain and extend runway, but it also gives management an incentive to sell stock into the rally, which caps upside after the initial squeeze. DRIO is the only name here where improving operating leverage can plausibly support a durable multiple, while ADVM, ICCM, WATT and SPCE remain much more dependent on capital markets than on earnings power.

The contrarian miss is that a rising P/E is being treated as a breakout signal when, for this cohort, the more predictive variable is balance-sheet durability plus revision momentum. If forward estimates do not move up by the next reporting cycle, the market will likely fade the move and reprice these names back toward financing discount. For now the cleaner expression is to own the one with monetization traction and hedge or short the most cash-burn-sensitive names, rather than buying the whole screen.

Key Decisions for Investors

• Long DRIO on pullbacks over the next 2-6 weeks; best risk/reward in the group if management can keep revenue revisions moving up. Invalidate if the stock loses the prior breakout and the next update fails to show upward guidance pressure.
• Pair trade: long DRIO / short SPCE for 1-3 months. Thesis is monetization quality versus capital-intensity risk; target a 15-20% relative spread, stop if SPCE secures financing or a material operational milestone that extends runway.
• Use ADVM, ICCM and WATT primarily as momentum shorts into strength over the next 1-2 months if they rally without fresh clinical/commercial catalysts. The risk is headline-driven squeezes, so keep size modest and cover on any announced financing or binary event progress.
• Do not chase the full basket mechanically; wait for post-screen consolidation. The screen itself is not enough to justify a multi-week long unless a name also shows positive estimate revision and no near-term dilution overhang.